Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Jul 30;20(9):520. doi: 10.1038/s41577-020-0408-0

NK cells in COVID-19: protectors or opponents?

Aljawharah Alrubayyi 1,
PMCID: PMC7391014  PMID: 32732951

Natural killer (NK) cells contribute to early antiviral immunity, and in this preprint, Maucourant et al. report reduced NK cell counts in the peripheral blood of 27 patients hospitalized with moderate or severe COVID-19. In early COVID-19, NK cell activation across distinct subsets was elevated in peripheral blood, mirroring the activation signature of NK cells in the bronchoalveolar lavage fluid of patients with COVID-19. Interestingly, severe hyperinflammation was associated with the proliferation and activation of ‘adaptive’ NK cells, a specialised sub-population with enhanced antibody-dependent cellular cytotoxicity, as well as the arming of CD56bright NK cells with cytotoxic molecules. These results suggest that a distinct NK cell immunophenotype is associated with the severity of COVID-19. Further studies are necessary to define the protective antiviral versus the detrimental pathological roles of NK cells in patients with COVID-19.

Competing interests

The author declares no competing interests.

References

Original article

  1. Maucourant C, et al. Natural killer cell activation related to clinical outcome of COVID-19. medRxiv. 2020 doi: 10.1101/2020.07.07.20148478v1. [DOI] [Google Scholar]

Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES